OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2023
(2)
2026
(1)
2022
(1)
2021
(1)
2019
(1)
2018
(1)
2017
(1)
2013
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension.
Not available
S-EPMC3555052
|
biostudies-literature
Cite
Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study.
Not available
S-EPMC9306160
|
biostudies-literature
Cite
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
Not available
S-EPMC5324272
|
biostudies-literature
Cite
Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis.
Not available
S-EPMC10238522
|
biostudies-literature
Cite
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
Not available
S-EPMC6440009
|
biostudies-literature
Cite
Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure.
Not available
S-EPMC10192237
|
biostudies-literature
Cite
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.
Not available
S-EPMC8579532
|
biostudies-literature
Cite
Biological tumor volume predicts survival in recurrent High-Grade glioma: A multiparametric [<sup>18</sup>F]FET PET/MRI study.
Not available
S-EPMC12830414
|
biostudies-literature
Cite
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
Not available
S-EPMC5753452
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets